Preparation method and application of microcapsule type nano composite material

By combining photothermal and acoustic dynamic therapy in microcapsules, the thermal response polymer of APS and PDA can be used to achieve synergistic treatment of tumors, which solves the poor solubility and side effects of traditional chemotherapy drugs in cancer treatment, and improves the therapeutic effect and safety sex.

CN119074694AActive Publication Date: 2024-12-06SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411178210.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-06
Estimated Expiration
2044-08-27

AI Technical Summary

Technical Problem

Traditional chemotherapy drugs have limited success in cancer treatment due to factors such as poor solubility, non-targeted distribution, short half-life, and toxic side effects on normal tissues, and it is difficult to achieve specific tumor treatment.

Method used

Using microcapsules with ammonium persulfate (APS) particles as the core and thermally responsive polymer (TRP) with a new high-critical solution temperature (UCST) containing polydopamine (PDA) as the shell, the deep free radicals of tumors are controlled through logic gates. Release, combined with photothermal and acoustic dynamic therapy, achieve synergistic treatment of tumors.

Benefits of technology

Prolong the time of circulation of drugs in the body, improve the efficiency of drug enrichment in tumors, reduce toxic side effects on normal tissues, improve the effect of cancer treatment, and reduce side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074694A_ABST
    Figure CN119074694A_ABST
Patent Text Reader

Abstract

The invention relates to a preparation method of a'microcapsule 'type nano composite material. The'microcapsule' type nano composite material is a material for controlling release of tumor deep free radicals through a logic gate. The preparation method comprises the step of generating a microcapsule on the surface of APS by adopting an in-situ polymerization method so as to form a core-shell structure. According to the preparation method of the microcapsule type nano composite material, the microcapsule which takes ammonium persulfate (APS) particles as a core and a novel high critical solution temperature (UCST) thermal response polymer (TRP) containing polydopamine (PDA) as a shell has mild photo-thermal capacity and a good temperature controlled release effect, and preparation of a tumor sonodynamics-photo-thermal synergistic treatment medicine is realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of anti-tumor drug preparation, and more specifically, to a preparation method of a "microcapsule" type nanocomposite material and its application. Background Art

[0002] Cancer has become a major public health issue that seriously threatens human life and health. Chemotherapy has become one of the most commonly used methods for treating cancer patients because of its simplicity and convenience. However, traditional chemotherapy drugs have limited success due to factors such as poor solubility, non-targeted distribution, short half-life, toxic side effects on normal tissues, and multidrug resistance. Therefore, it is particularly important to achieve specific tumor treatment with minimal side effects on normal tissues or cells through the rational design of specific drugs and the assistance of precise treatment methods. With the rapid development of nanotechnology, the combination of material science, nanotechnology and new treatment methods has become an extraordinary and efficient tumor treatment method.

[0003] Nanomaterials have good dispersibility, stable structure, and unique physical and chemical properties. They can be used as drug delivery systems to prolong the circulation time of drugs in the blood and enrich more drugs in tumor sites. Thermoresponsive polymers (TRPs) are used as drug carriers to achieve thermal stimulation controlled release and are used in cancer treatment to improve the therapeutic efficiency of delivered drugs or biomolecules because of their reversible and temperature-dependent structural transitions between hydrophilic and hydrophobic phases. New treatment methods are mainly photothermal therapy (PTT), photodynamic therapy (PDT), or sonodynamic therapy (SDT) triggered by light or ultrasound. Because phototherapy is non-invasive, efficient, safe, and has excellent spatiotemporal selectivity, and ultrasound therapy has a large penetration depth and low side effects, the combined treatment of the two can greatly improve the effect of cancer treatment and reduce side effects. Summary of the invention

[0004] The present invention provides a preparation method and application of a "microcapsule" type nanocomposite material, wherein the microcapsule has ammonium persulfate (APS) particles as the core and a new high critical solution temperature (UCST) thermal responsive polymer (TRP) containing polydopamine (PDA) as the shell, and has mild photothermal capacity and good temperature-controlled release effect, thereby realizing sonodynamic-photothermal synergistic therapy of tumors.

[0005] According to one aspect of the present invention, a method for preparing a "microcapsule" type nanocomposite material is provided, characterized in that the "microcapsule" type nanocomposite material is a material that controls the release of free radicals deep in the tumor through logic gates; the preparation method includes using an in situ polymerization method to generate microcapsules on the APS surface to form a "core-shell" structure.

[0006] Based on the above scheme, the method for preparing the "microcapsule" type nanocomposite material preferably comprises the following steps:

[0007] Step 1, using dimethyl sulfoxide (DMSO) as a co-solvent to dissolve by ultrasonication to obtain a mixed solution of dopamine hydrochloride (DA·HCl) solution, acrylonitrile and acrylamide;

[0008] Step 2, disperse ammonium persulfate (APS) and polyvinyl pyrrolidone (PVP) in chloroform, mechanically stir at room temperature for 30 minutes, and then move into a 60°C oil bath. Use an injector to add dopamine hydrochloride solution, acrylonitrile (AN) and acrylamide (AM) mixed solution at a rate of 1-3 drops / second, stir at 60°C for 5 hours under nitrogen conditions, and the polymerization is completed.

[0009] Preferably, based on the above scheme, the mass ratio of acrylonitrile (AN) to acrylamide (AM) is 1:5.41.

[0010] Preferably, based on the above scheme, step 2 includes in detail: dispersing the APS particles in a chloroform continuous phase containing PVP, wherein PVP is a surfactant, and the hydrophilic lactam group in PVP extends into the APS, and the hydrophobic methylene group extends into the oil phase chloroform, thereby preventing the aggregation of the APS particles and achieving in situ polymerization on the surface of the APS particles.

[0011] Preferably, based on the above scheme, in step 2, APS is the initiator of dopamine monomer and acts as a template in the formation process of microcapsules. After adding dopamine hydrochloride solution, acrylonitrile and acrylamide mixed solution, in situ polymerization occurs on the APS surface to form microcapsules with APS as the core and TRP / PDA composite shell.

[0012] Preferably, based on the above scheme, a microcapsule with a shell of a thermally responsive polymer (TRP / PDA) with a high critical solution temperature (UCST) synthesized from dopamine hydrochloride, acrylonitrile and acrylamide is used, the high critical solution temperature, i.e., the solution temperature, is below the temperature transition point, and the microcapsule structure is spherical. When the temperature rises above the temperature transition point, the microcapsule structure changes from a spherical shape to a coil shape, releasing the APS core.

[0013] Based on the above scheme, it is preferred that the microcapsules are shelled with a thermoresponsive polymer (TRP / PDA) with a high critical solution temperature (UCST) synthesized from dopamine hydrochloride, acrylonitrile and acrylamide. Under the irradiation of 808nm near-infrared light, PDA will convert light energy into heat energy, so that the temperature of the microcapsules reaches above UCST, thereby exerting a mild photothermal therapy (PTT) effect.

[0014] The "microcapsule" type nanocomposite material controls the release of free radicals deep in the tumor by logic gates. Under the stimulation of ultrasound (US), APS produces sulfate free radicals at the tumor site, resulting in a Fenton-like reaction, achieving the effect of synergistic treatment of tumors with photothermal therapy and sonodynamic therapy.

[0015] The present invention also provides an application of the "microcapsule" type nanocomposite material in the synergistic treatment of tumors by photothermal therapy and sonodynamic therapy.

[0016] Preferably, the above scheme includes the following steps: first, under the irradiation of near-infrared light, the temperature of the microcapsule reaches above UCST, the structure of TRP changes from a spherical form to a coil form, and then the APS particles are released, and then US stimulation is applied.

[0017] The invention discloses a method for preparing a "microcapsule" type nanocomposite material. Ammonium persulfate (APS) particles with sonodynamic effect are coated in a novel high critical solution temperature (UCST) thermoresponsive polymer (TRP) containing polydopamine (PDA). Only by utilizing the absorption of polydopamine in the near infrared (NIR) region to convert light energy into heat energy, and after reaching the critical solution temperature, the structure of the thermoresponsive polymer can be transformed from a spherical form to a coil form, and ammonium persulfate can be released, thereby preparing a type of bionic nanocomposite drug carrier, which can effectively avoid complex biological barriers in the body, prolong the circulation time of nanoparticles in the blood in the body, achieve efficient enrichment of nanoparticles in tumors, reduce the toxic side effects of drugs in the body, and finally realize the combined sonodynamic-photothermal therapy of tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0019] In the figure:

[0020] Figure 1 This is the transmission electron microscopy image of APS@TRP / PDA in Example 1.

[0021] Figure 2-1 This is the particle size diagram of APS@TRP / PDA in Example 1.

[0022] Figure 2-2 This is a graph showing the change in particle size of APS@TRP / PDA over time in Example 1.

[0023] Figure 3 It is the temperature transition point of TRP in APS@TRP / PDA in Example 1.

[0024] Figure 4 This is a diagram of the photothermal heating effect of different concentrations of APS@TRP / PDA in Example 1.

[0025] Figure 5-1 This is a diagram showing the ROS detection effect of different concentrations of APS@TRP / PDA in Example 1 under ultrasound alone or light irradiation followed by ultrasound stimulation;

[0026] Figure 5-2 This is a diagram showing the ROS detection effect of APS@TRP / PDA at the same concentration in Example 1 under the stimulation of light first and then ultrasound or ultrasound first and then light;

[0027] Figure 6-1 The APS release curves of APS@TRP / PDA at different temperatures within 24 hours in Example 1;

[0028] Figure 6-2 The APS release curves of APS@TRP / PDA within 10 min at different temperatures in Example 1;

[0029] Figure 7 The cytotoxicity test results of APS@TRP / PDA in Example 1;

[0030] Figure 8 This is the live-dead staining image of APS@TRP / PDA in Example 1;

[0031] Fig. 9 This is the in vivo photothermal imaging image of APS@TRP / PDA mice in Example 1;

[0032] Figure 10-1 This is a graph showing the tumor growth curve of APS@TRP / PDA mice in Example 1;

[0033] Figure 10-2 This is the anatomical tumor volume and weight curve of APS@TRP / PD mice in Example 1. DETAILED DESCRIPTION

[0034] The specific implementation of the present invention is further described in detail below in conjunction with the accompanying drawings and examples. The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention.

[0035] It should be understood that when used in this specification and the appended claims, the term “comprising” indicates the presence of described features, integers, steps, operations, elements and / or components, but does not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or collections.

[0036] In order to simplify the drawings, only the parts related to the present invention are schematically shown in each figure, and they do not represent the actual structure of the product. In addition, in order to simplify the drawings and facilitate understanding, in some figures, only one of the parts with the same structure or function is schematically drawn or marked. In this article, "one" not only means "only one", but also means "more than one".

[0037] It should be further understood that the terms “and / or” used in the specification and appended claims refer to any and all possible combinations of one or more of the associated listed items, and include these combinations.

[0038] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the specific implementation methods of the present invention will be described below with reference to the accompanying drawings. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings and other implementation methods can be obtained based on these drawings without creative work.

[0039] See also Figure 1 , and combined with Figure 2 and Figure 3 As shown, a method for preparing a "microcapsule" type nanocomposite material of the present invention comprises the following steps:

[0040] Step 1, using dimethyl sulfoxide (DMSO) as a co-solvent to dissolve by ultrasonication to obtain a mixed solution of dopamine hydrochloride (DA·HCl) solution, acrylonitrile and acrylamide;

[0041] Step 2, ammonium persulfate (APS) and polyvinyl pyrrolidone (PVP) are dispersed in chloroform, mechanically stirred at room temperature for 30 minutes, and then moved into an oil bath at 60°C. Dopamine hydrochloride solution, acrylonitrile (AN) and acrylamide (AM) mixed solution are added thereto at a rate of 1-3 drops / second using an injector, and stirred at 60°C for 5 hours under nitrogen conditions. In situ polymerization occurs on the surface of APS to form microcapsules with APS as the core and TRP / PDA composite shell.

[0042] Wherein, the mass ratio of acrylonitrile (AN) to acrylamide (AM) is 1:5.41.

[0043] Specifically, step 2 includes in detail dispersing APS particles in a chloroform continuous phase containing PVP, extending the hydrophilic lactam group in PVP to APS, and extending the hydrophobic methylene group to the oil phase chloroform, and polymerizing in situ on the surface of APS particles.

[0044] The microcapsules are shelled with a thermoresponsive polymer (TRP / PDA) with a high critical solution temperature (UCST) synthesized from dopamine hydrochloride, acrylonitrile and acrylamide. When the temperature is below the UCST, the structure is spherical. When the temperature rises above the UCST, the structure changes from a spherical shape to a coil shape, releasing the APS core.

[0045] The microcapsules of the present invention are shelled with a thermoresponsive polymer (TRP / PDA) with a high critical solution temperature (UCST) synthesized from acid dopamine, acrylonitrile and acrylamide. Under the irradiation of 808nm near-infrared light, PDA converts light energy into heat energy, so that the temperature of the microcapsules reaches above UCST, thereby exerting a mild photothermal therapy (PTT) effect.

[0046] The present invention also provides an application of a "microcapsule" type nanocomposite material that controls the release of free radicals deep in the tumor through logic gates in the synergistic treatment of tumors with photothermal therapy and sonodynamic therapy.

[0047] When used, the method includes the following steps: first, under the irradiation of near-infrared light, the temperature of the microcapsule reaches above UCST, the structure of TRP changes from a spherical form to a coil form, and then the APS particles are released, and then US stimulation is applied.

[0048] In order to illustrate the effects of the present invention, specific embodiments are described in detail below.

[0049] The reagents used in the following examples are all common commercial products, and the "water" used refers to "deionized water" unless otherwise specified. The PBS buffer used in the following examples has a concentration of 10 mM unless otherwise specified.

[0050] Example 1

[0051] The preparation method of a "microcapsule" type nanocomposite material for controlling the release of deep-layer free radicals in tumors by logic gates of the present invention comprises the following specific steps:

[0052] In-situ polymerization was used, and dimethyl sulfoxide (DMSO) was used as a co-solvent for ultrasonic dissolution to obtain dopamine hydrochloride (DA·HCl) solution, acrylonitrile and acrylamide mixed solution. 2gAPS and 0.3gPVP were dispersed in 30mL chloroform solution, mechanically stirred at room temperature for 30min, and then moved into an oil bath at 60℃. Dopamine hydrochloride (DA·HCl) solution, acrylonitrile and acrylamide mixed solution were slowly added to the oil bath using an injector, stirred for 5h under nitrogen protection, and polymerization was completed. After the obtained microcapsules were precipitated with acetone, they were washed three times with water and anhydrous ethanol alternately to remove unreacted APS and residual dispersant.

[0053] The morphology of APS@TRP / PDA obtained in Example 1 was observed under a transmission electron microscope. Figure 1 As shown by Figure 1 It can be seen that the APS surface is covered by a lighter-colored TRP / PDA shell layer with a size of about 150 nm.

[0054] In order to verify whether the particle size of the material is stable in the culture medium, the APS@TRP / PDA obtained in Example 1 was dispersed in DMEM complete culture medium (containing 10% fetal bovine serum) and the particle size change within one week was measured. Figure 2-2 and Figure 2-1 As shown, the particle size fluctuation of APS@TRP / PDA detected by laser particle size analyzer within 7 days was not obvious, indicating that the material designed in this application has good anti-protein adsorption performance and excellent in vivo stability, which is conducive to achieving stable and effective long-term circulation of the material in vivo.

[0055] The temperature transition point of TRP is determined by measuring the change in turbidity of the polymer solution with temperature, and is defined here as the temperature corresponding to 50% transmittance at 808 nm (polymer concentration is 1 wt%). Figure 3 It can be seen that the temperature transition point of TRP in Example 1 is at 42°C.

[0056] In order to examine the photothermal performance of APS@TRP / PDA, a FLIR ONE Pro infrared thermal imager was used to test the photothermal performance of APS@TRP / PDA obtained in Example 1 under 808 nm laser irradiation.

[0057] The specific experimental steps are as follows: the APS@TRP / PDA sample obtained in Example 1 was ultrasonically dispersed in water to prepare a dispersion solution, and an 808 nm laser (2 W / cm 2 ) irradiated 50, 100, 150, 200 μg / mL APS@TRP / PDA dispersions for 10 min and recorded the temperature change of the APS@TRP / PDA sample dispersions during the irradiation heating process every 10 s. Figure 4 As shown, after 10 minutes of laser irradiation, the dispersion temperatures of 50, 100, 150, and 200 μg / mL APS@TRP / PDA samples increased by 10.8°C, 18.5°C, 21.2°C, and 25.6°C, respectively.

[0058] Depend on Figure 4 It can be concluded that the photothermal effect of APS@TRP / PDA nanomaterial solution can be precisely controlled by regulating physical conditions and has good photothermal properties.

[0059] from Figure 5-1It can be found that under the same concentration conditions, the cumulative drug release rate of APS (the mass percentage of released drugs in the total drugs) increases with the increase of temperature. When the temperature reaches above the cloud point, the cumulative drug release rate is about 90%. In addition, Figure 5-2 This is a diagram of the cumulative drug release of APS in a shorter time. When APS@TRP / PDA of different concentrations is irradiated with 808nm near-infrared light, as the concentration increases, the more PDA contained in the material, the stronger the ability to convert light energy into heat energy, and the easier it is to reach the temperature transition point (42°C). Only when the temperature transition point is reached will the release of APS increase sharply, so as to perform sonodynamic therapy. At the same time, it can also prevent APS from leaking when circulating in the body (around 37°C), ensuring the biosafety of the material.

[0060] In order to detect ROS in the APS@TRP / PDA aqueous solution, the present invention uses a 2',7'-dichlorofluorescein diacetate (DCFH-DA) reactive oxygen species detection kit to detect the generation of ROS.

[0061] Since CFH-DA itself has no fluorescence, after DA is removed in an alkaline environment, the non-fluorescent DCFH generated is oxidized by ROS to generate fluorescent DCF. Therefore, the amount of ROS generated can be detected by detecting the fluorescence intensity of DCF.

[0062] DCFH-DA (5 μL, 10 mM) was dissolved in NaOH (200 μL, 0.01 M) and allowed to stand at room temperature for 30 min. PBS (2.3 mL, 10 mM) was added to dilute to 20 μM. 50 μL was taken and mixed with the APS@TRP / PDA sample obtained in Example 1. The fluorescence changes at different pH values ​​were detected by molecular fluorescence spectrometer. The excitation and emission wavelengths were set to 488 nm and 498-700 nm, respectively. The incident and exit slit widths were set to 10 nm and 20 nm, respectively. The emission voltage was 500 V and the scanning speed was 1200 nm min. -1 .

[0063] In order to detect the in vitro drug release of APS@TRP / PDA, APS was dissolved in PBS buffer solutions (pH=7.4) at different temperatures to prepare APS solutions, and the conductivity of APS was detected using a conductivity meter. After three independent tests, the data were statistically processed and the average value was taken. The origin software was used to draw a standard curve of APS concentration and conductivity intensity value, and the APS standard curve equation was obtained.

[0064] Calculation of drug loading and encapsulation efficiency of APS@TRP / PDA: Since APS is soluble in water but insoluble in organic solvents, after precipitating the product with acetone, all the supernatants obtained by washing with water and centrifugation were used to measure the drug loading DLC ​​and encapsulation efficiency DLE. The specific calculation formulas are shown in the following formulas (1) and (2). The supernatant was measured with a conductivity meter, and the mass of APS in the supernatant was determined based on the above standard curve.

[0065] The mass of drug loaded = the mass of drug delivered - the mass of APS in the supernatant.

[0066] DLC (wt.%) = (loaded drug mass / drug-loaded APS@TRP / PDA mass) × 100% (1); DLE (wt.%) = (loaded drug mass / administered drug mass) × 100% (2);

[0067] The total amount of APS in the supernatant was calculated to be about 192 mg from the standard curve of APS, and the amount of APS was 2 g, so the encapsulation efficiency was calculated to be about 90.4%. The mass of the product APS@TRP / PDA was 7.26 g, so the drug loading of APS@TRP / PDA was calculated to be 24.9%. It can be seen that the prepared TRP / PDA has a high encapsulation loading performance for anticancer drug molecules.

[0068] The APS@TRP / PDA obtained in Example 1 was subjected to in vitro drug release testing. 1 mL of the APS@TRP / PDA APS@TRP / PDA obtained in Example 1 (1 mg / mL, prepared with pH=7.4 PBS buffer) was added to a dialysis bag (MWCO=3500).

[0069] Subsequently, the dialysis bag was completely immersed in a test tube containing 10 mL of PBS solution (pH = 7.4), and the test tube was placed in a shaker at 25°C, 37°C, and 45°C. 3 mL of PBS external solution was taken out at a predetermined time interval, and 3 mL of the corresponding PBS buffer was added. The conductivity of the APS taken out of the external solution was then measured using a conductivity meter, and the amount of APS, i.e., the in vitro cumulative drug release, was calculated based on the standard curve of APS.

[0070] Based on the above results, the effects of different concentrations of materials on the release of APS under external stimulation (808nm irradiation) were further studied.

[0071] Depend on Figure 6-1 , 6-2 It can be seen that the amount of ROS generated by APS@TRP / PDA after light irradiation followed by ultrasound is the largest, and there is a burst release effect within 10 minutes, which indicates the in vitro logic gate controlled release effect of the material.

[0072] Cytotoxicity test of APS@TRP / PDA obtained in Example 1:

[0073] Tumor cells (4T1 cells) were all frozen cell materials from the inventor's laboratory, and the cell culture medium was purchased DMEM culture medium containing 10% fetal bovine serum albumin and 1% double antibody (penicillin-streptomycin) (hereinafter referred to as DMEM complete culture medium). All cells were incubated in the cell culture medium and cultured in a cell culture incubator containing 5% CO2 at 37°C.

[0074] The CCK-8 kit was used to detect the cytotoxicity of APS@TRP / PDA materials on normal cells (3T3 cells) and tumor cells (4T1 cells). The CCK-8 kit is a rapid and highly sensitive detection kit widely used in cell proliferation and cytotoxicity, which can be reduced to generate yellow water-soluble formazan. The more and faster the cell proliferation, the darker the color; the greater the cytotoxicity, the lighter the color.

[0075] The detection method is as follows: Using a 96-well plate, mouse breast cancer cells (4T1) were seeded at a density of 5×103 cells / well in 100 μL of DMEM complete medium containing 10% FBS. After the 96-well plate was placed in a 37°C incubator (5% CO2) for 24 hours, 100 μL of a series of APS@TRP / PDA DMEM complete medium solutions with a concentration gradient were added to each column (the same concentration in the same column). After the cells were placed in a 37°C incubator (5% CO2) for 24 hours in the dark, 20 μL of CCK-8 solution was added to each well (try to avoid bubbles during the addition process), and the cells were incubated in a 37°C incubator (5% CO2) for another 4 hours. The absorbance value (OD) at 450 nm was measured using an ELISA reader to calculate the relative cell viability. The OD value in the cytotoxicity experiment was the average of 6 independent parallel samples, and the results were expressed as mean ± standard deviation (SD). The relative cell viability is usually calculated according to formula (3):

[0076] Viability(%)=(ODsample / ODcontrol) × 100 (3)

[0077] Among them, ODcontrol represents the cell absorbance value detected before the addition of APS@TRP / PDA, ODsample represents the cell absorbance value detected after the addition of APS@TRP / PDA material; Viability represents the relative cell viability.

[0078] In addition, CCK-8 kit was used to detect

[0079] Group ①APS@TRP / PDA,

[0080] Group ②APS@TRP / PDA+US,

[0081] Group ③ APS@TRP / PDA+Laser,

[0082] Group ④APS@TRP / PDA+US+Laser,

[0083] Group ⑤APS@TRP / PDA+Laser+US,

[0084] ("+Laser" means: replace the above "incubate in the dark for 24 hours" with: "after incubating in the dark for 4 hours, irradiate with 808nm laser (2W / cm2) for 5 minutes, and then return to 37°C incubator (5% CO2) for incubation in the dark for 20 hours", "+US" means: replace the above "incubate in the dark for 24 hours" with: "after incubating in the dark for 4 hours, use ultrasonic therapy device (1.5W / cm2) for ultrasound for 5 minutes, and then return to 37°C incubator (5% CO2) for incubation in the dark for 20 hours", "+US+Laser" means: replace the above "incubate in the dark for 24 hours" with: "after incubating in the dark for 4 hours, use ultrasonic therapy device (1.5W / cm2) for ultrasound for 5 minutes, then irradiate with 808nm laser (2W / cm2) for 5 minutes, and then return to 37°C incubator (5% CO2) for incubation in the dark for 20 hours",

[0085] "+Laser+US" means: the above "incubate in the dark for 24 hours" is replaced by: "After incubating in the dark for 4 hours, irradiate with 808nm laser (2W / cm2) for 5 minutes, then use ultrasonic therapy device (1.5W / cm2) for 5 minutes, and then return to 37°C incubator (5% CO2) and incubate in the dark for 20 hours"). The cytotoxicity in 4T1 cells was used as the control group, and the experimental steps were the same as above.

[0086] Test results such as Figure 7As shown in the figure, mouse breast cancer cells (4T1) were used as the experimental subjects. The horizontal axis is the PDA concentration in the APS@TRP / PDA materials with different concentrations (calculated according to the standard curve of PDA absorbance at 808nm). The experimental results show that: in the absence of light, the material APS@TRP / PDA has almost no lethality to 4T1 cells; under the action of US alone, the material APS@TRP / PDA cannot release a large amount of APS, so the cell survival rate of 4T1 cells at the highest concentration is as high as 70%; under the action of only 808nm laser (power of 2W / c m2) When irradiated for 5 minutes, when the material APS@TRP / PDA is at the highest concentration, although APS is released in large quantities, no free radicals can be generated without ultrasound, so there is only a photothermal effect, and the survival rate of 4T1 cells is as high as more than 60%; under the condition of ultrasound first and then light irradiation, the cell survival rate is still high; and only when light is applied first, PDA converts light energy into heat energy, and the temperature reaches above the temperature transition point, TRP / PDA changes from a spherical structure to a coil structure, releasing a large amount of APS, and then US is applied, APS generates a large amount of ·S2O82-, and the cell survival rate is the lowest at this time, less than 20%. These experimental results show that APS@TRP / PDA has the characteristics of logic gate control of free radical release deep in the tumor, and its application in the field of anti-cancer enhances the effect of sonodynamic-photothermal combined therapy.

[0087] A live-dead staining experiment was performed on APS@TRP / PDA. The experimental method is as follows:

[0088] Calcein-AM and propidium iodide (PI) co-staining technology can visually classify live / dead cells through green / red fluorescence.

[0089] The detection method is as follows: Using confocal dishes, mouse breast cancer cells (4T1) were inoculated at a density of 6×104 cells / well in 2 mL of DMEM complete medium containing 10% FBS. Confocal dishes were divided into the following according to the different stimuli applied:

[0090] Group ①APS@TRP / PDA,

[0091] Group ②APS@TRP / PDA+US,

[0092] Group ③ APS@TRP / PDA+Laser,

[0093] Group ④APS@TRP / PDA+US+Laser,

[0094] Group ⑤APS@TRP / PDA+Laser+US,

[0095] After culturing in a 37°C incubator (5% CO2) for 24 hours, aspirate the DMEM complete medium and add DMEM complete medium solution containing APS@TRP / PDA (200μg / mL, 2mL) to each column. Continue incubating in a 37°C incubator (5% CO2) for 4 hours and then apply stimulation according to the group. After completion, continue to place the Confocal dishes in a 37°C incubator (5% CO2) for 4 hours and observe the fluorescence effect under Confocal.

[0096] Depend on Figure 8 It can be seen that almost all 4T1 cells in APS@TRP / PDA were stained with green fluorescence, and about 20% of the red cells in APS@TRP / PDA+US, APS@TRP / PDA+Laser, and APS@TRP / PDA+US+Laser groups were found. Only the 4T1 cells in APS@TRP / PDA+Laser+US group were stained red and shrunken into small balls, losing their normal morphology, indicating that all cells were dead. This result is consistent with the results of CCK-8 assay.

[0097] To further investigate the photothermal effect of APS@TRP / PDA on tumors in vivo, photothermal imaging experiments were performed on mice. The experimental results are as follows: Fig. 9 As shown, it can be obtained from Fig. 9 It can be seen that the in vivo photothermal effect of APS@TRP / PDA is good.

[0098] 4T1 tumor cells (1.2×106) were subcutaneously injected into the right hind flank of BALB / c mice to establish a 4T1 tumor transplantation model. When the tumor volume reached 100 mm3, the mice were randomly divided into three groups (3 mice in each group).

[0099] Group ①APS@TRP / PDA+Light,

[0100] Group ②APS@TRP / PDA+US+Light, (Light: 808nm, 2W / cm2, 10min)

[0101] Group ③APS@TRP / PDA+Light+US, (US: 1.5W / cm2, 10min)

[0102] 100μL APS@TRP / PDA (2mg / mL) was injected through the tail vein, and stimulated by +Laser, +Laser+US, +US+Laser, etc. After 12h, the thermal infrared imager was used to detect the photothermal imaging and tumor temperature changes of the tumor site at different time points (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10min) under 808nm laser (2W / cm2). Under the same near-infrared light irradiation conditions, the temperature of the tumor site treated with the nanomaterial group rose rapidly, reaching about 49.2℃.

[0103] It is generally believed that when the temperature of cancer cells reaches above 42.5°C, the cell survival rate will drop sharply. When the temperature of cancer cells exceeds 50°C, the cancer cells can be killed within a few minutes. Therefore, the photothermal imaging and temperature change results of the tumor site can effectively prove that the APS@TRP / PDA nanomaterial can effectively convert light energy into heat energy under 808nm near-infrared light and has a certain killing performance on tumor cells.

[0104] Finally, the mouse tumor growth curve, anatomical tumor volume and weight experiments were performed, and the 4T1 tumor-bearing mouse model was established by subcutaneously injecting 4T1 tumor cells (1.2×106 cells) into the right hind limb of BALB / C mice. When the tumor volume of the mouse reached about 100mm 3 BALB / C mice bearing 4T1 tumors were randomly divided into 5 groups (6 mice in each group) and injected with 100 μL of the corresponding materials via tail vein injection, with an intravenous injection dose of 2 mg / mL.

[0105] Group ①PBS;

[0106] Group ②APS@TRP / PDA;

[0107] Group ③APS@TRP / PDA+US, (US: 1.5W / cm2, 10min);

[0108] Group ④APS@TRP / PDA+Light;

[0109] Group ⑤APS@TRP / PDA+US+Light, (Light: 808nm, 2W / cm2, 10min);

[0110] Group ⑥APS@TRP / PDA+Light+US, (Light: 808nm, 2W / cm2, 10min);

[0111] The body weight and tumor size of the mice were measured every two days for the following 3 weeks. After 21 days of treatment, all the mice were sacrificed, and the tumors were removed and weighed.

[0112] Among them, the tumor growth curve of APS@TRP / PDA mice is shown in Figure 10-1 , the anatomical tumor volume and weight curves are as follows Figure 10-2 As shown. Figure 10-1 , 10-2 It can be seen that the tumor volume of all treatment groups except the PBS group decreased during the treatment period, but only the treatment group with photothermal therapy followed by ultrasound had the smallest tumor volume after treatment.

[0113] The present invention encapsulates ammonium persulfate (APS) particles with sonodynamic effect in a novel high critical solution temperature (UCST) thermoresponsive polymer (TRP) containing polydopamine (PDA). Only by utilizing the absorption of polydopamine in the near-infrared (NIR) region to convert light energy into heat energy, and after reaching the critical solution temperature, the structure of the thermoresponsive polymer can be transformed from a spherical form to a coil form, and ammonium persulfate can be released, thereby preparing a class of bionic nanocomposite drug carriers to effectively avoid complex biological barriers in the body, prolong the circulation time of nanoparticles in the blood in the body, achieve efficient enrichment of nanoparticles in tumors, reduce the toxic and side effects of drugs in the body, and ultimately achieve tumor sonodynamic-photothermal combined treatment.

[0114] Finally, the method of the present application is only a preferred implementation scheme and is not intended to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing a "microcapsule" type nanocomposite material, characterized in that: The "microcapsule" type nanocomposite material is a material that controls the release of free radicals deep in the tumor through logic gates; the preparation method includes using an in-situ polymerization method to generate microcapsules on the surface of APS to form a "core-shell" structure.

2. The method for preparing the "microcapsule" type nanocomposite material according to claim 1, characterized in that: The following steps are involved: Step 1, using dimethyl sulfoxide (DMSO) as a co-solvent to dissolve by ultrasonication to obtain a mixed solution of dopamine hydrochloride (DA·HCl) solution, acrylonitrile and acrylamide; Step 2, disperse ammonium persulfate (APS) and polyvinyl pyrrolidone (PVP) in chloroform, mechanically stir at room temperature for 30 minutes, and then move into a 60°C oil bath. Use an injector to add dopamine hydrochloride solution, acrylonitrile (AN) and acrylamide (AM) mixed solution at a rate of 1-3 drops / second, stir at 60°C for 5 hours under nitrogen conditions, and the polymerization is completed.

3. The method for preparing the "microcapsule" type nanocomposite material according to claim 2, characterized in that: The mass ratio of acrylonitrile (AN) to acrylamide (AM) is 1:5.

41.

4. The method for preparing a "microcapsule" type nanocomposite material as claimed in claim 2, characterized in that: Step 2 specifically includes dispersing APS particles in a chloroform continuous phase containing PVP, extending the hydrophilic lactam group in PVP to APS, and extending the hydrophobic methylene group to the oil phase chloroform, and polymerizing in situ on the surface of APS particles.

5. The method for preparing the "microcapsule" type nanocomposite material according to claim 2, characterized in that: In step 2, after adding dopamine hydrochloride solution, acrylonitrile and acrylamide mixed solution, in-situ polymerization occurs on the surface of APS to form microcapsules consisting of APS as a core and TRP / PDA composite shell.

6. The method for preparing a "microcapsule" type nanocomposite material as claimed in claim 5, characterized in that: The microcapsules are shelled with a thermoresponsive polymer (TRP / PDA) with a high critical solution temperature (UCST) synthesized from dopamine hydrochloride, acrylonitrile and acrylamide. When the temperature is below the UCST, the structure is spherical. When the temperature rises above the UCST, the structure changes from a spherical shape to a coil shape, releasing the APS core.

7. The method for preparing a "microcapsule" type nanocomposite material as claimed in claim 5, characterized in that: Microcapsules with a shell of a thermoresponsive polymer (TRP / PDA) with a high critical solution temperature (UCST) synthesized from dopamine, acrylonitrile and acrylamide, under the irradiation of 808nm near-infrared light, PDA will convert light energy into heat energy, making the temperature of the microcapsules reach above UCST, thus exerting a mild photothermal therapy (PTT) effect.

8. Use of the "microcapsule" type nanocomposite material according to any one of claims 1 to 5 in the synergistic treatment of tumors with photothermal therapy and sonodynamic therapy.

9. The use of a "microcapsule" type nanocomposite material as claimed in claim 8, characterized in that: The method comprises the following steps: first, under the irradiation of near-infrared light, the temperature of the microcapsule reaches above UCST, the structure of TRP changes from a spherical form to a coil form, and then the APS particles are released, and then US stimulation is applied.

Citation Information

Patent Citations

  • A nano-capsule type polydopamine drug material and method for preparing the same

    AU2020104156A4

  • Nitrogen-enriched carbon shell cladded nano core-shell-structure carbonaceous carrier as well as preparation method and application thereof

    CN106711457A

  • Temperature-responsible photothermal nanomaterial and preparation method thereof

    CN110204659A

  • Folic acid grafted polydopamine temperature-sensitive polymer core-shell microgel, preparation method and application of microgel in preparation of in-vitro drug controlled release drugs

    CN116492289A

  • Preparation method and application of red cell membrane biomimetic modified core-shell type nano composite material

    CN118161626A